Stability-indicating UPLC-PDA Method for Ambrisentan Tablets and Identification of a Main Degradation Product by UPLC-MS/MS

Author(s): Rodolfo Ortigara, Martin Steppe, Cássia Virginia Garcia*.

Journal Name: Current Pharmaceutical Analysis

Volume 16 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Ambrisentan is a drug used to treat the pulmonary arterial hypertension symptoms, commercialized as coated tablets. Drug quality control is an essential part for the development and release of drugs for consumption; however, there are few studies related to the proposition of analytical methods and stability study for ambrisentan.

Objective: The development of an UPLC assay of ambrisentan in tablets with degradation product`s elucidation was proposed.

Methods: Tests with different solvents and chromatographic columns were carried out, achieving an optimal condition using mobile phase in gradient mode, Waters® BEH C18 column and detection at 260 nm.

Results: Satisfactory system suitability was obtained (theoretical plates, sensitivity and resolution among peaks), with a reduced analysis time (6 minutes). The method was validated in accordance with the international guidelines and it demonstrated adequate specificity, either for the drug assay as for the identification and quantification of degradation product. It showed linearity (r= 0.999), accuracy (degradation products recovery: 98.47 - 102.44; assay recovery: 99.98 - 104.32%) and precision (RSD: 0.69), with limits of quantification and detection in suitable magnitude in order to evaluate possible drug degradation.

Conclusion: UPLC method demonstrated to be fast with satisfactory robustness. The main ambrisentan degradation product formed under thermal stress conditions was elucidated by UPLC-MS/MS and its structure was suggested.

Keywords: Ambrisentan, UPLC, validation, degradation product, elucidation, thermal stress.

[1]
Galié, N.; Barberá, J.A.; Frost, A.; Ghofrani, H.; Hoeper, M.M.; McLaughlin, V.; Peacock, A.; Simonneau, G.; Vachiery, J.; Grunig, E.; Oudiz, R.; Vonk-Noordegraaf, A.; White, R.; Blair, C.; Gillies, H.; Miller, K.; Harris, J.; Langley, J.; Rubin, L. Inicial use of ambrisentanplus tadalafil in pulmonary arterial hypertension. N. Engl. J. Med., 2015, 373, 834-844.
[2]
Ahmed, S.; Palevsky, H.I. Pulmonary arterial hypertension related to connective tissue disease: a review. Rheum. Dis. Clin. NA., 2014, 40(1), 103-124.
[3]
Oudiz, R.J.; Allard, M.; Blair, C.; Gillies, H. Ambrisentan therapy in patients with pulmonay arterial hypertension: 3 year outcome. Chest, 2012, Suppl., 3-7.
[4]
Douša, M.; Gibala, P. Rapid determiantion of ambrisentan enantiomers by enantioselective liquid chromatography using cellulose-based chiral stationary phase in reverse phase mode. J. Sep. Sci., 2012, 35(7), 798-803.
[5]
Orlandini, S.; Paquini, B.; Caprini, C.; Del Bubba, M.; Douša, M.; Pinzauti, S.; Furlanetto, S. Enantioseparation and impurity determination of ambrisentan using cyclodextrine-modified micellar electrokinetic chromatography: visualizing the design space within quality by design framework. J. Chrom. A., 2016, 1467, 363-371.
[6]
Krait, S.; Douša, M.; Scriba, G. Quality by design-guided development of capillary electrophoresis method for the chiral purity determination of ambrisentan. Chromatographia, 2016, 79, 1343-1350.
[7]
Nirogi, R.; Kandikere, V.; Komarneni, P.; Aleti, R.; Padala, N.; Kalaikadhiban, I. LC-ESI-MS/MS method for quantification of ambrisentan in plasma and application to rat pharmacokinetic study. Biomed. Chromatogr., 2012, 26(10), 1150-1156.
[8]
Garcia-Martínez, S.; Rico, E.; Casal, E.; Grisaleña, A.; Alcaraz, E.; King, E.; Leal, N.; Navarro, I.; Campanero, M.A. Bioanalytical validation study for the determination of unbound ambrisentan in human plasma using rapid equilibrium dialysis followed by ultra performance liquid chromatography coupled to mass spectrometry. J. Pharm. Biomed. Anal., 2018, 150, 427-435.
[9]
Basak, A.K.; Raw, A.S.; Al Hakim, A.H.; Furness, S.; Samaan, N.I.; Gill, D.S.; Patel, H.B.; Powers, R.F.; Yu, L. Pharmaceutical impurities: regulatory perspective for abbreviated new drug applications. Adv. Drug Deliv. Rev., 2007, 59(1), 64-72.
[10]
Yokoyama, Y.; Tomatsuri, M.; Hayashi, H.; Hirai, K.; Ono, Y.; Yamada, Y.; Todoroki, K.; Toyo’oka, T.; Yamada, K.; Itoh, K. Simultaneous microdetermination of bosentan, ambrisentan, sildenafil and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension. J. Pharm. Biomed. Anal., 2014, 89, 227-232.
[11]
Narayana, M.B.V.; Chandrasekhar, K.B.; Rao, B.M. A validated specific stability-indicating PR-HPLC assay method for ambrisentan and its related substances. J. Chromatogr. Sci., 2013, 52(8), 818-825.
[12]
Ramisetti, N.R.; Kuntamukkala, R. LC-MS/MS characterization of forced degradation products of ambrisentan: development and validation of a stability-indicating RP-HPLC method. New J. Chem., 2014, 38(7), 3050-3061.
[13]
Brazil, Agência Nacional de Vigilância Sanitária, RDC 166 - Validação de Métodos Analíticos 2017.
[14]
International Council for Harmonisation - ICH. Q2(R1), Technical Requirements for the Registration of Pharmaceutical for Human Use, Validation of Analytical Procedures, Text and Methodology , 2005.
[15]
Baertschi, S.W.; Alsante, K.M.; Reed, R.A. Pharmaceutical stress testing: predicting drug degradation; Taylor & Francis: Boca Raton, 2005.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 1
Year: 2020
Page: [55 - 63]
Pages: 9
DOI: 10.2174/1573412914666181003140449
Price: $65

Article Metrics

PDF: 13
HTML: 3

Special-new-year-discount